Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab.
Yonesaka, Kimio; Zejnullahu, Kreshnik; Okamoto, Isamu; Satoh, Taroh; Cappuzzo, Federico; Souglakos, John; Ercan, Dalia; Rogers, Andrew; Roncalli, Massimo; Takeda, Masayuki; Fujisaka, Yasuhito; Philips, Juliet; Shimizu, Toshio; Maenishi, Osamu; Yonggon Cho; Sun, Jason; Destro, Annarita; Taira, Koichi; Takeda, Koji; Okabe, Takafumi; Science Translational Medicine, 2011, vol. 3, issue 99, p 1, ISSN 19466234. ISBN 19466234.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef